These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1094 related articles for article (PubMed ID: 471128)

  • 41. Multiple cutaneous malignant melanomas with features of primary melanoma.
    Unger SW; Wanebo HJ; Cooper PH
    Ann Surg; 1981 Feb; 193(2):245-50. PubMed ID: 7469560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Letter: Malignant melanoma arising de novo within a B.C.G. scarification site.
    Lokich JJ
    Lancet; 1975 Feb; 1(7902):331-2. PubMed ID: 46469
    [No Abstract]   [Full Text] [Related]  

  • 44. Pneumonitis with oral bcg.
    Schapira DV; McPherson TA
    N Engl J Med; 1977 Feb; 296(7):397. PubMed ID: 834203
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effect of intra-tumoral injection of tuberculin-active protein on growth of transplantable mouse melanomas].
    Saida T
    Nihon Hifuka Gakkai Zasshi; 1982 Nov; 92(13):1389-98. PubMed ID: 6984864
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment of disseminated malignant melanoma with high-dose oral BCG.
    Varella AD; Bandiera DC; de Amorim AR; Calvis LA; Santos IO; Escaleira N; Gentil F
    Cancer; 1981 Sep; 48(6):1353-62. PubMed ID: 7023654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological effects of BCG in malignant melanoma: two modes of administration compared.
    Bluming AZ; Vogel CL; Ziegler JL; Mody N; Kamya G
    Ann Intern Med; 1972 Mar; 76(3):405-11. PubMed ID: 5015915
    [No Abstract]   [Full Text] [Related]  

  • 48. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical and histologic correlation of melanoma regression after intralesional BCG therapy: a case report.
    Mastrangelo MJ; Kim YH; Bornstein RS; Chee DO; Sulit HL; Yarbro JW; Prehn RT
    J Natl Cancer Inst; 1974 Jan; 52(1):19-24. PubMed ID: 4590009
    [No Abstract]   [Full Text] [Related]  

  • 50. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL; Jessup JM; Cohen MH
    Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The immune response in human malignant melanoma.
    Mackie RM
    Clin Exp Dermatol; 1976 Mar; 1(1):23-8. PubMed ID: 773575
    [No Abstract]   [Full Text] [Related]  

  • 54. B.C.G. in malignant melanoma.
    Baker MA; Taub RN
    Lancet; 1973 May; 1(7812):1117-8. PubMed ID: 4122031
    [No Abstract]   [Full Text] [Related]  

  • 55. The biologic activity of MER-BCG in experimental systems and preliminary clinical studies.
    Mikulski SM; Muggia FM
    Cancer Treat Rev; 1977 Jun; 4(2):103-17. PubMed ID: 329986
    [No Abstract]   [Full Text] [Related]  

  • 56. Management of recurrent melanoma of the extremity.
    Shingleton WW; Seigler HF; Stocks LH; Downs RW
    Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy].
    Glinkina LS; Bruvere RZh
    Vopr Onkol; 1992; 38(6):659-66. PubMed ID: 1300766
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ; Garnick MB; Legg M
    Oncology; 1979; 36(5):236-41. PubMed ID: 481845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCG in the treatment of human cancer.
    Terry WD
    CA Cancer J Clin; 1975; 25(4):198-203. PubMed ID: 805639
    [No Abstract]   [Full Text] [Related]  

  • 60. Alterations of the clinically noninvolved skin in patients with malignant melanoma. An electron microscopic study before and after repeated application of BCG.
    Szekeres L; Orfanos CE
    Dermatologica; 1978; 156(3):142-54. PubMed ID: 624428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.